Analyst David Novak works at STIFEL and is focused on the Healthcare sector with 29 price targets and ratings documented since 2018 spanning on 5 stocks. Previously, David Novak worked at RAYMOND JAMES. Analyst's average stock valuation to be materialised ratio is 60.71% with an average time for price targets to be met of 127.25 days.
Most recent stock forecast was given on ZYME, Zymeworks Inc at 10-Dec-2021.
David Novak best performing recommendations are on LPTX.
The best stock recommendation documented was for LPTX at 9/13/2021. The price target of $4 was fulfilled within 17 days with a profit of $2.23 (125.99%) receiving and performance score of 74.11.
Average potential price target upside